---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037924"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:05:02.945810+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q2 net loss widens to $128.6M; cuts 2023 spend by 15%, completes SEQUOIA-HCM enrollment

## Summary
- Net loss of $128.6M ($1.34 loss per share) vs $19.8M ($0.23 loss) in Q2 2022.
- Revenue fell to $0.9M from $89.0M, primarily due to no mavacamten royalty revenue in 2023.
- Cash, equivalents and investments $592.6M at June 30, 2023.
- Completed enrollment in SEQUOIA-HCM with 282 patients; topline results expected by end of 2023.
- Revised 2023 operating expense guidance to $390-410M; net cash utilization ~$310-320M, saving ~15%.

## SEC filing metadata
- accession: 0000950170-23-037924
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/0000950170-23-037924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/cytk-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037924
- JSON: https://secwatch.observer/filing/0000950170-23-037924.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037924.txt

## Key facts
- Earnings Releases
  CYTOKINETICS INC updated its second quarter of 2023 guidance (reaffirmed).
  - Period: second quarter of 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On August 3, 2023, Cytokinetics, Incorporated (the "Registrant") announced its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/0000950170-23-037924-index.htm
- Earnings Releases
  CYTOKINETICS INC updated its 2023 guidance (lowered).
  - Period: 2023
  - Guidance: lowered
  - Result: guidance update
  source text: The company today revised its financial guidance due to the reduction in expected operating expenses following the receipt of a CRL from the FDA regarding the New Drug Application for omecamtiv mecarbil and the discontinuation of COURAGE-ALS, the Phase 3 trial of reldesemtiv. The company anticipates operating expenses for 2023 will be in the range of $390 to $410 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/0000950170-23-037924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.